Company: BIAF
Filing Date: 2025-05-15
Form Type: 10-Q
Source: 0001641172-25-010787
Chunk: 75

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-05-15
Form: 10-Q
Item: Part I, Item 8
Chunk 75
---
 to ensure that information required to be disclosed by a company in the reports that it files or submits under the
Exchange Act is accumulated and communicated to the Company’s management, including its principal executive and principal financial
officers, or persons performing similar functions, as appropriate, to allow timely decisions regarding required disclosure. We have adopted
and maintain disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) that are designed
to provide reasonable assurance that information required to be disclosed in the reports filed under the Exchange Act, such as this Quarterly
Report on Form 10-Q, is collected, recorded, processed, summarized, and reported within the time periods specified in the rules of the
SEC. The Company’s disclosure controls and procedures are also designed to ensure that such information is accumulated and communicated
to management to allow timely decisions regarding required disclosure. As of March 31, 2025, the end of the period covered by this Quarterly
Report, our Chief Executive Officer and Chief Financial Officer evaluated the effectiveness of our “disclosure controls and procedures,”
as defined in Rule 13a-15(e) under the Exchange Act. The Chief Executive Officer and Chief Financial Officer assessed the effectiveness
of our disclosure controls and procedures as of March 31, 2025. Based on their assessment, they have concluded that as of March 31, 2025,
our disclosure controls and procedures are effective.

Changes in Internal Control over Financial Reporting

There were no changes in our internal controls (as
defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) over financial reporting during the three months ended March 31, 2025,
the period covered by this Quarterly Report, that could materially affect, or are reasonably likely to materially affect, our internal
control over financial reporting.

23

PART II

ITEM 1. LEGAL PROCEEDINGS.

From time to time, we are involved in various disputes
and litigation matters that arise in the ordinary course of business. To date, we have had no material pending legal proceedings, and
we are not engaged in any legal proceedings that are expected, individually or in the aggregate, to have a material adverse impact on
our financial position or results of operations.

ITEM 1A. RISK FACTORS.

In addition to other information set forth in this
Quarterly Report, you should carefully consider the “Risk Factors” discussed in the 202